DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-668/S-009

AstraZeneca LP
Attention: Ms. Cindy M. Lancaster
1800 Concord Pike
P.O. Box 8355
Wilimington, DE 19803-8355

Dear Ms. Lancaster,

Please refer to your supplemental new drug application dated September 12, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for LEXXEL (enalapril maleate/felodipine ER) 5/2.5 and 5/5mg Tablets.

This "Changes Being Effected" supplemental new drug application proposes the following changes:

1. Under **CLINICAL PHARMACOLOGY**, **Pharmacodynamics** the words "(See PRECAUTIONS, Drug Interactions.)" have been added for consistency with the FDA approved text for VASOTEC.

2. Under **PRECAUTIONS, Drug Interactions** the following text has been added for consistency with FDA approved labeling for VASOTEC:

   In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC. In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC. However, reports suggest that NSAIDS may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking NSAIDS concomitantly with ACE inhibitors.

At the time of the next printing, add enalapril maleate in parenthesis after VASOTEC in the above paragraph, e.g., VASOTEC (enalapril maleate).

3. Under **Storage,** the revision date, date of copyright and part number have been updated.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling. Accordingly, the supplemental application is approved effective on the date of this letter.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call:

Ms. Denise M. Hinton
Regulatory Health Project Manager
(301) 594-5333

Sincerely,

{See appended electronic signature page}

Douglas C. Throckmorton, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Doug Throckmorton
6/11/03 09:47:05 AM